Drugs / SER-214
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02579473 | Jan 2016 → Dec 2023 | Parkinson disease | Serina Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SER-214 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02579473 ↗ |
| Action | Activate | “potent dopamine agonist” NCT02579473 ↗ |
| Modality | Other / unclassified | “poly (2-ethyl-2oxazoline)(POZ) polymer conjugate” NCT02579473 ↗ |
| Route | Subcutaneous | “SER-214 will be administered subcutaneously once a week” NCT02579473 ↗ |